Apremilast: pooled safety analysis of three phase 3, randomized, controlled trials in patients with psoriatic arthritis

被引：0
|
作者：
Schett, G. [1 ]
Mease, P. J. [2 ,3 ]
Kavanaugh, A. [4 ]
Adebajo, A. O. [5 ]
Gomez-Reino, J. J. [6 ]
Wollenhaupt, J. [7 ]
Cutolo, M. [8 ]
Lespessailles, E. [9 ]
Shah, K.
Hu, C.
Stevens, R.
Edwards, C. [10 ]
Birbara, C. [11 ]
机构：
[1] Univ Erlangen Nurnberg, D-91054 Erlangen, Germany
[2] Swedish Med Ctr, Seattle, WA USA
[3] Univ Washington, Sch Med, Seattle, WA USA
[4] Univ Calif San Diego, San Diego, CA 92103 USA
[5] Univ Sheffield, Sheffield, S Yorkshire, England
[6] Hosp Clin Univ, Santiago, Spain
[7] Schon Klin Hamburg Eilbek, Hamburg, Germany
[8] Univ Genoa, Genoa, Italy
[9] Univ Orleans, Orleans, France
[10] Southampton Univ Hosp, Southampton, Hants, England
[11] Univ Massachusetts, Sch Med, Worcester, MA USA
来源：
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY | 2013年 / 27卷
关键词：
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
P012
引用
收藏
页码：6 / 6
页数：1
相关论文
共 50 条
  • [41] SECUKINUMAB SAFETY AND TOLERABILITY IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS AND PSORIASIS: RESULTS FROM A POOLED SAFETY ANALYSIS OF SEVEN INTERNATIONAL PHASE 3 TRIALS
    Soriano, Enrique
    Gottlieb, Alice
    McInnes, Ian B.
    Mease, Philip
    Mpofu, Shephard
    Widmer, Albert
    JCR-JOURNAL OF CLINICAL RHEUMATOLOGY, 2016, 22 (03) : 140 - 140
  • [42] Apremilast, an Oral Phosphodiesterase 4 Inhibitor, in Patients with Psoriatic Arthritis: Results of a Phase 3, Randomized, Controlled Trial.
    Kavanaugh, Arthur
    Mease, Philip J.
    Gomez-Reino, Juan J.
    Adewale, Adebajo
    Wollenhaupt, Juergen
    Hu, ChiaChi
    Stevens, Randall
    ARTHRITIS AND RHEUMATISM, 2012, 64 (12): : 4172 - 4173
  • [43] PROBABILITY AND IMPACT OF ACHIEVING LOW DISEASE ACTIVITY OR REMISSION IN PATIENTS WITH PSORIATIC ARTHRITIS TREATED WITH APREMILAST: POOLED ANALYSIS OF THE PALACE 1-3 PHASE 3 TRIALS
    McInnes, I.
    Mease, P. J.
    Behrens, F.
    Orbai, A. -M.
    Brunori, M.
    Teng, L.
    Guerette, B.
    Smolen, J.
    ANNALS OF THE RHEUMATIC DISEASES, 2018, 77 : 1588 - 1589
  • [44] Long-term safety and tolerability of apremilast in patients with psoriasis: Pooled safety analysis for ≥156 weeks from 2 phase 3, randomized, controlled trials (ESTEEM 1 and 2)
    Crowley, Jeffrey
    Thaci, Diamant
    Joly, Pascal
    Peris, Ketty
    Papp, Kim A.
    Goncalves, Joana
    Day, Robert M.
    Chen, Rongdean
    Shah, Kamal
    Ferrandiz, Carlos
    Cather, Jennifer C.
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2017, 77 (02) : 310 - +
  • [45] Safety and Tolerability of Secukinumab in Patients With Active Ankylosing Spondylitis: Pooled Safety Analysis of Two Phase 3, Randomized, Controlled Trials
    Kyburz, D.
    Deodhar, A.
    Baeten, D.
    Sieper, J.
    Porter, B.
    Widmer, A.
    Richards, H.
    SWISS MEDICAL WEEKLY, 2016, 146 : 6S - 6S
  • [46] Apremilast, an Oral Phosphodiesterase 4 Inhibitor, Is Associated with Long-Term (104-Week) Improvement in Fatigue in Patients with Psoriatic Arthritis: Pooled Results from 3 Phase 3, Randomized, Controlled Trials
    Kavanaugh, Arthur
    Gladman, Dafna
    Edwards, Christopher J.
    Poder, Airi
    Liote, Frederic
    Bird, Paul A.
    Schett, Georg
    McIlraith, Melissa
    Teng, Lichen
    Mease, Philip J.
    ARTHRITIS & RHEUMATOLOGY, 2015, 67
  • [47] Safety and Tolerability of Secukinumab in Patients with Active Ankylosing Spondylitis: Pooled Safety Analysis of Two Phase 3, Randomized, Controlled Trials
    Deodhar, Atul A.
    Baeten, Dominique
    Sieper, Joachim
    Porter, Brian
    Widmer, Albert
    Richards, Hanno
    ARTHRITIS & RHEUMATOLOGY, 2015, 67
  • [48] A Phase III, Randomized, Controlled Trial of Apremilast in Patients with Psoriatic Arthritis: Results of the PALACE 2 Trial
    Cutolo, Maurizio
    Myerson, Gary E.
    Fleischmann, Roy M.
    Liote, Frederic
    Diaz-Gonzalez, Federico
    Van den Bosch, Filip
    Marzo-Ortega, Helena
    Feist, Eugen
    Shah, Kamal
    Hu, ChiaChi
    Stevens, Randall M.
    Poder, Airi
    JOURNAL OF RHEUMATOLOGY, 2016, 43 (09) : 1724 - 1734
  • [49] Long-term safety of apremilast treatment in psoriasis and psoriatic arthritis patients: pooled analysis for 156 weeks and beyond in the ESTEEM 1 and 2 and PALACE 1-3 phase 3 trials
    Crowley, Jeffrey
    Wollenhaupt, Jurgen
    Reich, Kristian
    Shah, Kamal
    Chen, Rongdean
    Mease, Philip J.
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2017, 76 (06) : AB162 - AB162
  • [50] Apremilast, an Oral Phosphodiesterase 4 Inhibitor, Is Associated with Improvement of Pain, Fatigue, and Disability in Patients with Psoriatic Arthritis: Results from 3 Phase 3, Randomized, Controlled Trials
    Gladman, Dafna D.
    Strand, Vibeke
    Kavanaugh, Arthur
    Mease, Philip
    Edwards, Christopher J.
    Cutolo, Maurizio
    Liote, Frederic
    Bird, Paul
    Stevens, Randall M.
    Teng, Lichen
    Hochfeld, Marla
    Schett, Georg A.
    ARTHRITIS & RHEUMATOLOGY, 2014, 66 : S691 - S691
12345